Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Hanauer, Stephen B.
September 2007
Gut;Sep2007, Vol. 56 Issue 9, p1181
Academic Journal
Since the introduction of infliximab to treat Crohn's disease, combination therapy, with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.


Related Articles

  • The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response? D'Haens, Geert R.; Panaccione, Remo; Higgins, Peter D. R.; Vermeire, Severine; Gassull, Miquel; Chowers, Yehuda; Hanauer, Stephen B.; Herfarth, Hans; Hommes, Daan W.; Kamm, Michael; Löfberg, Robert; Quary, A.; Sands, Bruce; Sood, A.; Watermayer, G.; Lashner, Bret; Lémann, Marc; Plevy, Scott; Reinisch, Walter; Schreiber, Stefan // American Journal of Gastroenterology;Feb2011, Vol. 106 Issue 2, p199 

    The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability,...

  • Rate and Predictors of Mucosal Healing in Patients with Inflammatory Bowel Disease Treated with Anti-TNF-Alpha Antibodies. Beigel, Florian; Deml, Matthias; Schnitzler, Fabian; Breiteneicher, Simone; Göke, Burkhard; Ochsenkühn, Thomas; Brand, Stephan // PLoS ONE;Jun2014, Vol. 9 Issue 6, p1 

    Objective: Mucosal healing (MH) is an important treatment goal in patients with inflammatory bowel disease (IBD), but factors predicting MH under medical therapy are largely unknown. In this study, we aimed to characterize predictive factors for MH in anti-TNF-alpha antibody-treated IBD...

  • Infliximab: A Review of Its Use in the Treatment of Inflammatory Bowel Disease. Marzo, Manuela; Felice, Carla; Rapaccini, Gian Lodovico; Guidi, Luisa; Armuzzi, Alessandro // Clinical Medicine Insights: Therapeutics;2011, Issue 3, p15 

    Infliximab is a chimeric monoclonal antibody against anti-tumour necrosis factor alpha that has changed the management of inflammatory bowel diseases. Our review describes its mean clinical and pharmacological features, in order to resume its efficacy in induction and maintenance of clinical...

  • Infliximab.  // Reactions Weekly;4/8/2006, Issue 1096, p14 

    Provides information on the case of a woman who used infliximab to treat Crohn's disease. Side effect of the drug; Comment on the case study.

  • Adalimumab strides forward in Crohn's disease.  // PharmacoEconomics & Outcomes News;9/19/2009, Issue 587, p5 

    The article discusses research which compared the cost effectiveness of adalimumab and infliximab for treating severely active Crohn's disease. It references a study by A. P. Yu et al published in the July 2009 issue of the journal "PharmacoEconomincs." Results of the study showed that fewer...

  • Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy.  // Inflammatory Bowel Disease Monitor;2010, Vol. 11 Issue 2, p81 

    The article discusses a retrospective and observational study which investigates the role of the combined azathioprine and infliximab therapies in treating patients with luminal Crohn's disease in France. Around 79% of the patients are claimed under azathioprine treatment before the infliximab...

  • An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease. Sandborn, William J.; Hanauer, Stephen; Loftus, Edward V.; Tremaine, William J.; Kane, Sunanda; Cohen, Russell; Hanson, Karen; Johnson, Therese; Schmitt, Debra; Jeche, Resa // American Journal of Gastroenterology;Oct2004, Vol. 99 Issue 10, p1984 

    BACKGROUND: We assessed the tolerability and clinical benefit of adalimumab, a human antibody to tumor necrosis factor (TNF), in patients with Crohn's disease who had previously received and responded to the chimeric anti-TNF antibody infliximab, but who no longer had a sustained response and/or...

  • Inflixmab as a possible treatment for the hemorrhagic type of Crohn’s disease. Tsujikawa, Tomoyuki; Nezu, Riichiro; Andoh, Akira; Saotome, Takao; Araki, Yoshio; Ishizuka, Yoshiyuki; Sasaki, Masaya; Koyama, Shigeki; Fujiyama, Yoshihide // Journal of Gastroenterology;2004, Vol. 39 Issue 3, p284 

    Acute lower gastrointestinal bleeding is a rare complication of Crohn’s disease (CD). Although anti-tumor necrosis factor-Α (TNF-Α, infliximab) therapy has been established for patients with inflammatory and fistulous CD, there has been little evidence on whether infliximab is...

  • Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease. Viola, Franca; Civitelli, Fortunata; Di Nardo, Giovanni; Barbato, Maria Beatrice; Borrelli, Osvaldo; Oliva, Salvatore; Conte, Francesca; Cucchiara, Salvatore // American Journal of Gastroenterology;Oct2009, Vol. 104 Issue 10, p2566 

    OBJECTIVES:The use of tumor necrosis factor-alpha (TNF-α) antagonists has changed the therapeutic strategy for Crohn's disease (CD). Adalimumab (ADA), a fully human anti-TNF-α monoclonal antibody, is an effective therapy for patients with CD, both naive patients and those intolerant or...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics